Cytosorbents Corporation (CTSO) Earns Daily News Impact Rating of 0.18

Media coverage about Cytosorbents Corporation (NASDAQ:CTSO) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytosorbents Corporation earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.5875409764094 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

Several research analysts recently issued reports on CTSO shares. ValuEngine upgraded shares of Cytosorbents Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Cytosorbents Corporation in a research report on Tuesday, September 26th. Maxim Group set a $10.00 target price on shares of Cytosorbents Corporation and gave the stock a “buy” rating in a research report on Monday, July 17th. Aegis restated a “buy” rating and set a $9.00 price target on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. Finally, B. Riley restated a “buy” rating and set a $11.25 price target on shares of Cytosorbents Corporation in a research report on Saturday, August 12th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $10.45.

Cytosorbents Corporation (NASDAQ CTSO) traded down 1.61% during mid-day trading on Friday, reaching $6.10. 50,837 shares of the company’s stock traded hands. Cytosorbents Corporation has a one year low of $3.30 and a one year high of $6.70. The firm’s market cap is $171.61 million. The firm’s 50-day moving average price is $5.71 and its 200 day moving average price is $4.86.

Cytosorbents Corporation (NASDAQ:CTSO) last issued its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. Cytosorbents Corporation had a negative net margin of 80.56% and a negative return on equity of 529.95%. The business had revenue of $3.57 million during the quarter, compared to analysts’ expectations of $3.29 million. On average, equities analysts forecast that Cytosorbents Corporation will post ($0.27) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thestockobserver.com/2017/10/13/cytosorbents-corporation-ctso-earns-daily-news-impact-rating-of-0-18.html.

About Cytosorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Insider Buying and Selling by Quarter for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply